LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix. See why SCD ...
Data Access Shouldnʼt Require a Translator In most enterprises, data access still feels like a locked room with SQL as the ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...
In a landmark advancement for Indian healthcare, doctors at FMRI, Gurugram, have reported exceptional success in curing ...
The first sickle cell disease patient has been enrolled in a Phase 1b trial testing iadademstat, Oryzon Genomics' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback